Commerzbank Aktiengesellschaft FI Raises Stock Position in CVS Health Corporation $CVS

Commerzbank Aktiengesellschaft FI raised its stake in shares of CVS Health Corporation (NYSE:CVS) by 19.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 64,971 shares of the pharmacy operator’s stock after purchasing an additional 10,795 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in CVS Health were worth $4,482,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Argyle Capital Management LLC increased its position in CVS Health by 0.7% during the 2nd quarter. Argyle Capital Management LLC now owns 30,417 shares of the pharmacy operator’s stock valued at $2,098,000 after purchasing an additional 200 shares during the period. IFP Advisors Inc grew its position in shares of CVS Health by 3.7% in the 2nd quarter. IFP Advisors Inc now owns 24,118 shares of the pharmacy operator’s stock worth $1,664,000 after buying an additional 862 shares during the period. Callan Family Office LLC grew its position in shares of CVS Health by 277.8% in the 2nd quarter. Callan Family Office LLC now owns 121,108 shares of the pharmacy operator’s stock worth $8,354,000 after buying an additional 89,053 shares during the period. Blair William & Co. IL grew its position in shares of CVS Health by 0.9% in the 2nd quarter. Blair William & Co. IL now owns 62,052 shares of the pharmacy operator’s stock worth $4,280,000 after buying an additional 525 shares during the period. Finally, Leo Wealth LLC purchased a new stake in shares of CVS Health in the 2nd quarter worth about $538,000. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Stock Performance

Shares of CVS stock opened at $76.78 on Friday. CVS Health Corporation has a one year low of $43.56 and a one year high of $79.20. The company’s 50-day moving average is $71.98 and its 200 day moving average is $67.59. The company has a market capitalization of $97.38 billion, a price-to-earnings ratio of 21.45, a price-to-earnings-growth ratio of 0.85 and a beta of 0.60. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.35. The firm had revenue of $98.92 billion for the quarter, compared to the consensus estimate of $94.87 billion. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The business’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.83 EPS. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts expect that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd will be issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date of this dividend is Thursday, October 23rd. CVS Health’s dividend payout ratio (DPR) is presently 74.30%.

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of recent research reports. Wolfe Research upped their target price on shares of CVS Health from $80.00 to $85.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Cowen reaffirmed a “buy” rating on shares of CVS Health in a research report on Monday, August 4th. Barclays upped their target price on shares of CVS Health from $80.00 to $87.00 and gave the stock an “overweight” rating in a research report on Thursday, September 4th. Baird R W raised shares of CVS Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of CVS Health in a research report on Saturday, September 27th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $79.80.

Insider Activity

In other news, Director Anne A. Finucane sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total transaction of $532,650.00. Following the sale, the director owned 22,156 shares of the company’s stock, valued at $1,573,519.12. This trade represents a 25.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.22% of the stock is currently owned by insiders.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.